Related Topics News -

     
 Title only   |   Print 
     
MSCI中國指數成分股更換 納入老鋪黃金及藥明合聯等

2025-08-08T  
《信而有證》醫藥及生科股輪流炒 藥明康德績後急升11% 資金吼石藥購17428 / 三生購18567

2025-07-29T  
《大行》招銀國際升三生製藥目標價至37.67元 維持「買入」評級

2025-07-29T  
《大行》交銀國際升三生製藥目標價至33元 維持「買入」評級

2025-07-29T  
《大行》瑞銀升三生製藥目標價至41元 看好SSGJ-707銷售表現

2025-07-28T  
《大行》匯豐研究列出次季最受國內主動型互惠基金/北水追捧H股(表)

2025-07-28T  
三生製藥與輝瑞許可協議生效 折讓17%發新股籌7.85億

2025-07-24T  
《大行》中金列出內地主動偏股型基金第二季按季增幅最多重倉港股(表)

2025-07-24T  
《大行》中金:內地公募基金上季增持生物醫藥、內銀及內險 個股信達生物、三生製藥與泡泡瑪特增持最多

2025-07-24T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.